https://hotcopper.com.au/threads/general-discussion.5330178/page-7559?post_id=55652505

Interesting diagram showing the range of trials for IHL.

Had a big run up lately and starting to feature on reddit which I am not sure is a good thing.

Lots of comparisons with higher value CBD /psychedelic listings in US in the run up to NASDAQ listing

https://hotcopper.com.au/attachments/image-png.3528341/?temp_hash=351e6dbd7c78ec88253f2334d5e8aca6

Copied from post on HC giving positive examples of NASDAQ listing

“Investor note that was put out by Canary Capital (holders)the other day:

This morning Incannex (ASX:IHL) announced that it had submitted its registration statement to the United States Securities and Exchange Commission (SEC) for a proposed initial public offering. We see this as a very positive step for the company for a number of reasons:

• The company will list on the Nasdaq main board under the code IXHL where the market places far higher valuations on companies involved in cannabis and psychedelic research compared to Australia.
• The company will gain exposure to a large group of investors based in North America which will lead to a dramatic increase in the number of people following the Incannex story.
• The IPO will raise a minimum of US$25m at a price to be determined which will provide sufficient funding to advance its six drug development programs for Obstructive Sleep Apnoea, Traumatic Brain Injury, Inflammatory Lung Conditions (ARDS, SAARDS, Pulmonary Neutrophilia), Rheumatoid Arthritis, Inflammatory Bowel Disease and Generalised Anxiety Disorder (GAD).
• Incannex has selected Roth Capital Partners to be the sole book-runner to the offering and companies they have raised for have substantially increased in value following listings on the NASDAQ (Imugene – ASX:IMU raised $24.6m at 3.6 cents per share, now trading at 29 cents per share; Lake Resources- ASX:LKE raised $20.6m at $0.165 cents per share, now trading at $0.60 are a couple of examples).

The valuations of companies in the psychedelic space are multiples of IHL’s market capitalisation. Cara Therapeutics (NASDAQ:CARA) is currently conducting clinical trials using an analgesic opioid peptide called difelikefalin to treat a condition called pruritis which is an unpleasant sensation that provokes the desire to scratch. The company is capitalised at US$637 million (A$880 million) with only one program underway compared to Incannex’s A$320m current market capitalisation with 6 programs. Another comparable is Compass Pathways (NASDAQ: CMPS) which currently has one psychedelic research program underway and a market capitalisation of US$1.29B (A$ 1.78B). Jazz Pharmaceuticals (NASDAQ: JAZZ) acquired GW Pharmaceuticals PLC for US$7.2B after their cannabidiol medicine Epidiolex® was approved by the FDA to treat epilepsy.

We believe Roth Capital Partners considers IHL is substantially undervalued given the number of programs the company currently has targeting unmet medical needs that can be fast tracked to commercialisation with the FDA. We also have confidence the psychedelic program will draw a lot of interest from the North American market given this is a unique trial combining psilocybin with psychotherapy to treat GAD; the first of its type globally.”

https://hotcopper.com.au/threads/ann-ihl-files-form-f-1-registration-statement-with-sec.6225824/page-2#post-55483434

Sydney, 18th August 2021. Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’) is pleased to announce the public filing of a registration statement on Form F-1 with the US Securities and Exchange Commission (the “SEC”). The filing relates to a proposed US public offering (the “Offering”) of American Depositary Shares (“ADSs”), each of which will represent 50 ordinary shares of Incannex. The registration statement is being lodged with ASX as part of this announcement.

Document says listing as soon as possible. Interested in outcome ofexamples of other companies doing the same

@Hogajo beat me to it but I think this really adds to the potiential value of the company’s IHL CBD formulations.

https://www.scientificamerican.com/article/psilocybin-therapy-may-work-as-well-as-common-antidepressant/

“70 percent of subjects in the psilocybin group responded to the treatment, compared with 48 percent of those in the SSRI group. The difference in remission rates was also statistically significant: the rate in the psilocybin group was 57 percent, and it was 28 percent in the escitalopram group.”

“People describe psychedelic therapy as 25 years of therapy in one afternoon. And it can absolutely feel like that, but it’s not a silver bullet—and it’s just an afternoon,” Schneider says. “The real magic in this is not in the dosing day, it’s in the work that you do afterward.”

Although the trial is targeting GAD which has a huge addressable market there is a real push back going on about the efficacy of anti depressants, particularly in children. I assume that once they have approval for the formulation/therapy combination it will be able to be applied to resistant depression with possible life changing effects.